Caris Life Sciences (NASDAQ:CAI) Trading Up 7.5% – Still a Buy?
by Renee Jackson · The Cerbat GemCaris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) was up 7.5% during mid-day trading on Monday . The company traded as high as $19.44 and last traded at $19.4050. Approximately 128,590 shares changed hands during trading, a decline of 95% from the average daily volume of 2,500,821 shares. The stock had previously closed at $18.05.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on CAI shares. Piper Sandler started coverage on Caris Life Sciences in a research note on Friday. They issued a “neutral” rating and a $21.00 target price for the company. Robert W. Baird lifted their price objective on Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Weiss Ratings reiterated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. The Goldman Sachs Group started coverage on Caris Life Sciences in a research report on Wednesday, April 1st. They issued a “buy” rating and a $27.00 price objective for the company. Finally, Canaccord Genuity Group reduced their target price on Caris Life Sciences from $30.00 to $22.00 and set a “hold” rating on the stock in a report on Friday, March 13th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $28.86.
Read Our Latest Research Report on CAI
Caris Life Sciences Stock Performance
The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35. The company has a market cap of $5.47 billion and a P/E ratio of -107.50. The company’s 50 day simple moving average is $19.55.
Caris Life Sciences (NASDAQ:CAI – Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. Caris Life Sciences’s quarterly revenue was up 125.4% on a year-over-year basis. During the same period in the previous year, the company earned ($1.73) EPS.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in CAI. Global Retirement Partners LLC increased its holdings in shares of Caris Life Sciences by 99,900.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after purchasing an additional 999 shares in the last quarter. Olistico Wealth LLC bought a new stake in Caris Life Sciences during the fourth quarter valued at about $31,000. MetLife Investment Management LLC grew its holdings in Caris Life Sciences by 84.0% during the fourth quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock valued at $45,000 after purchasing an additional 755 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in Caris Life Sciences during the fourth quarter valued at about $67,000. Finally, Federated Hermes Inc. purchased a new position in shares of Caris Life Sciences in the fourth quarter valued at about $81,000.
Caris Life Sciences Company Profile
Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.
Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.